ArticleAntimicrobial agents and chemotherapy2014
The production of reactive oxygen species is a universal action mechanism of Amphotericin B against pathogenic yeasts and contributes to the fungicidal effect of this drug.
Article in Antimicrobial agents and chemotherapy, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 129 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
129 citing papers in PubMed, 217 citations in OpenAlex.
- Cascading damage toProceedings of the National Academy of Sciences of the United States of America · 2026Article
- Anandamide Targets Membrane Integrity in Non-Journal of fungi (Basel, Switzerland) · 2026Article
- Article
- Emerging evidence for a multitude of mechanisms and factors that determine amphotericin B resistance in pathogenic fungi.Cell surface (Amsterdam, Netherlands) · 2026Review
- Chitosan-Coated Mesoporous Silica Nanoparticles Co-Loaded with Curcumin and Amphotericin B: A Drug Delivery Approach for Photodynamic Inhibition of Dual-Species Biofilms.Pharmaceutics · 2026Article
- Shifting Epidemiology and Antifungal Susceptibility Patterns of Clinical Fungal Isolates in an Intensive Care Unit (ICU) from Bucharest, Romania: A Retrospective Observational Study.Antibiotics (Basel, Switzerland) · 2026Article
- Polypharmacology in malaria treatment: single drugs, multiple mechanisms, greater impact.Trends in parasitology · 2026Review
- Identification and characterization of a novel broad-spectrum antifungal compound targeting theMicrobiology spectrum · 2026Article
- Stress-Activated Protein Kinase Pathways as Potential Targets for the Development of New Antifungals.Journal of fungi (Basel, Switzerland) · 2026Review
- Pathogenic Significance of Trypanosomatids: Progress in Drug Resistance, Control Strategies, and Artificial Intelligence.Interdisciplinary perspectives on infectious diseases · 2026Review
- A targeted drug-repurposing strategy identifies TavaboroleFrontiers in microbiology · 2026Article
- Essential oil fromFrontiers in fungal biology · 2026Article
- Amoebicidal effect of pyocyanin and its mechanism of action againstCurrent research in parasitology & vector-borne diseases · 2026Article
- Genetically Encoded Sensors for Monitoring Intracellular Redox Health of the Pathogenic FungusACS sensors · 2025Article
- Amphibian-Derived Peptide Analog TB_KKG6K: A Powerful Drug Candidate AgainstJournal of fungi (Basel, Switzerland) · 2025Article
- Novel use of hyperbaric oxygen treatment for treatment-resistant disseminated Saksenaea and Fusarium in a patient on extracorporeal membrane oxygenation (ECMO): a case report.Diving and hyperbaric medicine · 2025Article
- Antifungal Activity and Mechanism of the Novel Antimicrobial Peptide Jelleine-Ic Against Candida albicans.Current microbiology · 2025Article
- Low-level direct currents eradicate multi-drug-resistantChemical engineering journal (Lausanne, Switzerland : 1996) · 2025Article
- Antifungal Effects of the Phloroglucinol Derivative DPPG Against PathogenicAntibiotics (Basel, Switzerland) · 2025Article
- New antifungal strategies and drug development against WHO critical priority fungal pathogens.Frontiers in cellular and infection microbiology · 2025Review
69 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 5 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Amphotericin B (AMB) is an antifungal drug that binds to ergosterol and forms pores at the cell membrane, causing the loss of ions. In addition, AMB induces the accumulation of reactive oxygen species (ROS), and although these molecules have multiple deleterious effects on fungal cells, their specific role in the action mechanism of AMB remains unknown. In this work, we studied the role of ROS in the action mechanism of AMB. We determined the intracellular induction of ROS in 44 isolates of different pathogenic yeast species (Candida albicans, Candida parapsilosis, Candida glabrata, Candida tropicalis, Candida krusei, Cryptococcus neoformans, and Cryptococcus gattii). We also characterized the production of ROS in AMB-resistant isolates. We found that AMB induces the formation of ROS in all the species tested. The inhibition of the mitochondrial respiratory chain by rotenone blocked the induction of ROS by AMB and provided protection from the killing action of the antifungal. Moreover, this phenomenon was absent in strains that displayed resistance to AMB. These strains showed an alteration in the respiration rate and mitochondrial membrane potential and also had higher catalase activity than that of the AMB-susceptible strains. Consistently, AMB failed to induce protein carbonylation in the resistant strains. Our data demonstrate that the production of ROS by AMB is a universal and important action mechanism that is correlated with the fungicidal effect and might explain the low rate of resistance to the molecule. Finally, these data provide an opportunity to design new strategies to improve the efficacy of this antifungal.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.